MARATHON PATENT GROUP’S WHOLLY-OWNED SUBSIDIARY ORTHOPHOENIX, LLC, ENTERS INTO SETTLEMENT AND LICENSE AGREEMENT WITH OSSEON LLC
LOS ANGELES, CA — (Marketwired) — 09/23/15 — Marathon Patent Group, Inc. (NASDAQ: MARA) (“Marathon”), a patent licensing company, announced today that its wholly-owned subsidiary, Orthophoenix, LLC, has entered into a settlement and license agreement with Osseon LLC. The consideration to be paid by Osseon to Orthophoenix and all other commercial terms of the license agreement are confidential.
The Orthophoenix portfolio consists of patents, which relate to the treatment of bones including fractured and diseased bone elements. Claims coverage includes discharging a material into a bone cavity such that the bone assumes an expanded geometry. In addition to claims covering discharging a material into a bone structure the portfolio included additional patents and associated claims which address bone treatments in which an expandable structure is introduced into a collapsed bone and subsequently manipulated such that the structure forms an expanded geometry inside the bone. Exemplary patents in this portfolio include U.S. Patents 6,248,110, 6,280,456, 6,440,138, 7,044,954, and 6,863,672 with additional foreign patent grants providing International coverage.
About Marathon Patent Group
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon’s strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.
